MREO Insider Trading Activity and SEC Form 4 Filings
MREO insider trading summary
No open-market insider purchases or sales of Mereo BioPharma Group plc (MREO) have been reported on SEC Form 4 in the past 12 months.
Latest MREO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 13, 2024 | Christine Ann Fox | Chief Financial Officer | Sell | $81K (19,158 @ $4.22) |
| Sep 13, 2024 | John A. Lewicki | Chief Scientific Officer | Sell | $46K (10,937 @ $4.22) |
| Sep 13, 2024 | Charles Sermon | General Counsel | Sell | $88K (20,946 @ $4.22) |
| Sep 13, 2024 | Alexandra Hughes-Wilson | See Remarks | Sell | $69K (16,304 @ $4.22) |
| Sep 13, 2024 | Alexandra Hughes-Wilson | See Remarks | Sell | $355K (84,008 @ $4.22) |
| Sep 13, 2024 | Denise Scots-Knight | Chief Executive Officer | Sell | $253K (60,046 @ $4.22) |
| Sep 12, 2024 | John A. Lewicki | Chief Scientific Officer | Sell | $23K (5,212 @ $4.47) |
| Sep 12, 2024 | Christine Ann Fox | Chief Financial Officer | Sell | $41K (9,128 @ $4.47) |
| Sep 12, 2024 | Charles Sermon | General Counsel | Sell | $45K (9,980 @ $4.47) |
| Sep 12, 2024 | Denise Scots-Knight | Chief Executive Officer | Sell | $128K (28,611 @ $4.47) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.